Cancer Chemotherapy Update Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Regimen for Breast Cancer

[1]  D. Solimando,et al.  Cancer Chemotherapy Update - Fluorouracil, Epirubicin, and Cyclophosphamide (FEC100) for Breast Cancer , 2010 .

[2]  G. Dranitsaris,et al.  Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea , 2007, Current oncology.

[3]  M. Boyiadzis.  Hematology - Oncology Therapy , 2006 .

[4]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Perry,et al.  Hepatotoxicity of chemotherapy. , 2006, The oncologist.

[7]  Dongsheng Tu,et al.  Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Eichler,et al.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Ajani,et al.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Dobbs,et al.  Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. , 2003, European journal of cancer.

[11]  M. Piccart,et al.  Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Verweij,et al.  Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy , 2001, British Journal of Cancer.

[13]  M. Perry,et al.  Hepatotoxicity of chemotherapy. , 2001, Expert opinion on drug safety.

[14]  M. Beckwith,et al.  Prevention and Management of Antineoplastic Extravasation Injury , 2000 .

[15]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Keizer,et al.  Use of granisetron in patients refractory to previous treatment with antiemetics. , 1998, Anti-cancer drugs.

[17]  M. Martín,et al.  The severity and pattern of emesis following different cytotoxic agents. , 1996, Oncology.

[18]  T. Beck.  The pattern of emesis following high‐dose cyclophosphamide and the anti‐emetic efficacy of ondansetron , 1995, Anti-cancer drugs.

[19]  M. Soukop,et al.  A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin , 1994, Supportive Care in Cancer.

[20]  T. Stillwell,et al.  Cyclophosphamide‐induced hemorrhagic cystitis: A review of 100 patients , 1988, Cancer.

[21]  J. Hannigan,et al.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. , 1986, Cancer research.

[22]  R. J. Cersosimo,et al.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Geller,et al.  A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Larson.  What Is the Appropriate Management of Tissue Extravasation by Antitumor Agents? , 1985, Plastic and reconstructive surgery.

[25]  D. Larson.  Treatment of tissue extravasation by antitumor agents , 1982, Cancer.

[26]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[27]  V. Bramwell,et al.  The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer , 2012, Drugs.

[28]  D. Faulds,et al.  Epirubicin An Updated Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Breast Cancer , 2012 .

[29]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Merkel,et al.  Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. , 2010, Arthritis and rheumatism.

[31]  E. Perez,et al.  Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Smith,et al.  A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy , 2005, Journal of Cancer Research and Clinical Oncology.

[33]  M. Markman,et al.  Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions , 2001, Drug safety.

[34]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Espié,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Dorr,et al.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. , 1995, Cancer treatment reviews.

[37]  V. Bramwell,et al.  A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. , 1992, European journal of cancer.